Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
17 juin 2022 12h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
02 juin 2022 14h40 HE
|
Cingulate Inc.
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
24 mai 2022 06h45 HE
|
Cingulate Inc.
Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using...
Cingulate to Present at H.C. Wainwright Global Investment Conference
18 mai 2022 17h20 HE
|
Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
12 mai 2022 16h15 HE
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Presents at NobleCon18
26 avr. 2022 12h27 HE
|
Cingulate Inc.
KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug...